Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06351592
Other study ID # ALN-SOD-ALS-2351
Secondary ID 2023-510344-20-0
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date June 28, 2024
Est. completion date April 28, 2029

Study information

Verified date April 2024
Source Regeneron Pharmaceuticals
Contact Clinical Trials Administrator
Phone 844-734-6643
Email clinicaltrials@regeneron.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with amyotrophic lateral sclerosis (ALS) who have a mutation in a gene called the superoxide dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This is the first time that ALN-SOD will be given to people. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: - The effect the study drug has on specific biomarkers, which are molecules in the blood or in the fluid that surrounds the brain and spinal cord, known as cerebrospinal fluid (CSF) - How much study drug is in the blood and in the CSF, at different times - Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) - What effects the study drug has on ALS symptoms


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 42
Est. completion date April 28, 2029
Est. primary completion date April 28, 2029
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: 1. Weakness attributable to ALS and a SOD1 mutation that has been previously described as associated with ALS or is considered likely to cause ALS, as defined in the protocol 2. Slow vital capacity (SVC) =50% predicted value based on age, gender and height, measured in upright position 3. Body Mass Index (BMI) =35 kg/m2 at time of screening 4. If participants are taking riluzole, edaravone, or AMX0035, they must be on a stable dose for at least 4 weeks prior to initial dosing visit and are expected to remain at that dose until the end of the study 5. Platelet count >50,000/microliter 6. Has normal blood pressure readings, as defined in the protocol Key Exclusion Criteria: 1. Concurrent participation in another interventional clinical trial 2. Has had a tracheostomy 3. Has dementia, as assessed by the investigator 4. Has uncontrolled psychiatric disease, including psychosis, active or recent suicidal ideation, untreated major depression, in the past 30 days 5. Has a medical history of brain or spinal disease/injury that would interfere with the lumbar puncture (LP) process, CSF circulation or safety assessment, as defined in the protocol 6. Presence of an implanted shunt for the drainage of CSF or an implanted central nervous system (CNS) catheter 7. Presents any concern to the study investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study 8. Was hospitalized (ie, >24 hours) for any reason other than ALS within 30 days of the screening visit NOTE: Other protocol defined inclusion / exclusion criteria apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ALN-SOD
Administered by intrathecal (IT) injection
Other:
Diluent
Administered by IT injection
Drug:
Placebo (PB)
Administered by IT injection

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Regeneron Pharmaceuticals

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of treatment-emergent adverse event (TEAEs) in participants treated with ALN-SOD At week 4 and week 124
Primary Severity of TEAEs in participants treated with ALN-SOD At week 4 and week 124
Secondary Concentration of SOD1 protein in cerebrospinal fluid (CSF) over time Up to approximately week 124
Secondary Change in concentration of SOD1 protein in CSF over time Up to approximately week 124
Secondary Concentration of neurofilament light chain (NfL) in plasma over time Up to approximately week 124
Secondary Change in concentration of NfL in plasma over time Up to approximately week 124
Secondary Concentration of NfL in CSF over time Up to approximately week 124
Secondary Change in concentration of NfL in CSF over time Up to approximately week 124
Secondary Concentration of ALN-SOD in plasma over time Up to approximately week 124
Secondary Concentration of ALN-SOD in CSF over time Up to approximately week 124
Secondary Incidence of anti-drug antibodies (ADAs) to ALN-SOD in serum over time Up to approximately week 124
Secondary Titer of ADAs to ALN-SOD in serum over time Up to approximately week 124
See also
  Status Clinical Trial Phase
Completed NCT02365922 - Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Completed NCT01699451 - DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida
Completed NCT04577404 - Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) Phase 3
Terminated NCT03580616 - Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT01884571 - Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT02118805 - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Completed NCT00244244 - A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS Phase 2
Active, not recruiting NCT00420719 - Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS) N/A
Completed NCT02936635 - A Study for Patients Who Completed VITALITY-ALS (CY 4031) Phase 3
Withdrawn NCT04055532 - Biomarkers in Neurodegenerative Diseases
Completed NCT03645031 - Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease N/A
Completed NCT01786603 - Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT02559869 - Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
Completed NCT01592552 - A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
Completed NCT00403104 - Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT02424669 - Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients N/A
Completed NCT02017912 - Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS Phase 2
Completed NCT01366027 - PRISM Registry: Pseudobulbar Affect Registry Series N/A
Completed NCT00330681 - Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Phase 3
Completed NCT00876772 - Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) Phase 2/Phase 3